share_log

Novo Integrated Sciences | 10-Q: Q3 2024 Earnings Report

Novo Integrated Sciences | 10-Q: Q3 2024 Earnings Report

Novo Integrated Sciences | 10-Q:2024財年三季報
美股SEC公告 ·  07/19 17:11
Moomoo AI 已提取核心訊息
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to...Show More
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to a higher average principal balance of convertible notes. Novo Integrated Sciences also highlighted business developments such as the launch of MiTelemed+, the expansion of its healthcare services, and the development of health and wellness products. Looking ahead, the company plans to continue focusing on its three primary pillars: service networks, interconnected technology, and health and wellness products, to drive future growth.
Novo綜合科學報告了2024年5月31日截止季度的財務業績,營收爲315萬美元,略微下降,與去年同期329.3萬美元相比。由於營業費用和衍生負債公允價值變動的巨額虧損影響,公司的營業虧損由去年的143萬美元增至252萬零203美元。季度淨虧損高達1374萬零1903美元,大幅下降,去年同期爲149.7萬美元,主要是由於衍生負債和外匯兌換損失所致。九個月期間,營收增長了10%,達到1,021.4萬美元,但淨虧損也從去年的1,005.4萬美元增至2,116.8萬美元。公司的財務表現受到各種因素的影響,包括產品成本變化、更高的營業成本以及由於可轉換票據平均本金餘額的增加而導致的利息支出增加。Novo綜合科學還強調了業務發展的諸多方面,如推出MiTelemed+,擴展其醫療服務,以及開發健康與保健產品。展望未來,公司計劃繼續專注於其三大支柱:服務網絡、互聯科技和健康與保健產品,以推動未來的增長。
Novo綜合科學報告了2024年5月31日截止季度的財務業績,營收爲315萬美元,略微下降,與去年同期329.3萬美元相比。由於營業費用和衍生負債公允價值變動的巨額虧損影響,公司的營業虧損由去年的143萬美元增至252萬零203美元。季度淨虧損高達1374萬零1903美元,大幅下降,去年同期爲149.7萬美元,主要是由於衍生負債和外匯兌換損失所致。九個月期間,營收增長了10%,達到1,021.4萬美元,但淨虧損也從去年的1,005.4萬美元增至2,116.8萬美元。公司的財務表現受到各種因素的影響,包括產品成本變化、更高的營業成本以及由於可轉換票據平均本金餘額的增加而導致的利息支出增加。Novo綜合科學還強調了業務發展的諸多方面,如推出MiTelemed+,擴展其醫療服務,以及開發健康與保健產品。展望未來,公司計劃繼續專注於其三大支柱:服務網絡、互聯科技和健康與保健產品,以推動未來的增長。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息